Printer Friendly

SRI International Collaborates With China's National Shanghai Center for New Drug Safety Evaluation and Research.

Business Editors/Health/Medical Writers

MENLO PARK, Calif.--(BUSINESS WIRE)--Aug. 18, 2003

Agreement Will Decrease Cost of Preclinical Drug

Development to SRI's Customers

SRI International, an independent research organization, today announced a collaboration for preclinical drug development services with the National Shanghai Center for New Drug Safety Evaluation and Research (NDSER). SRI will outsource portions of preclinical research to NDSER, which will provide SRI and its customers with qualified drug development services at reduced costs. SRI believes that this collaboration should expand its pricing flexibilities and allow its customers to develop a larger range of drugs for the clinic.

"NDSER provides SRI with qualified yet extremely cost-competitive services necessary for the expanding preclinical projects that we and our clients are currently developing," said Glenn Rice, Ph.D., SRI's vice president of Biosciences. "By outsourcing portions of the drug development process to NDSER, we can substantially decrease development costs and pass on the savings to our customers. The key differentiator is closely managed oversight of the work in Shanghai by a core staff of experts here in the U.S."

Through its team of qualified researchers and staff in Menlo Park, SRI offers clients high-quality, FDA-directed preclinical drug development. By utilizing the experience of the NDSER staff, SRI can further reduce costs for preclinical development. SRI will provide technical and regulatory oversight to the NDSER to assist compliant execution of its services.

"We are very pleased to work with SRI International, one of the leading U.S. drug discovery and development research organizations," said Qibing Mei, M.D., Ph.D., director of the National Shanghai Center for New Drug Safety Evaluation and Research. "We are particularly impressed with SRI's longstanding quality in FDA-compliant studies and look forward to providing similar quality services to SRI."

"I am very pleased about SRI and NDSER's mutually beneficial collaboration. Shanghai has strong advantages in life sciences and biotechnology," said Dr. Yi-Peng Li, chairman of the Shanghai Science and Technology Commission. "Recently, Shanghai has had significant developments in new drug research and development, and this environment is improving all the time. This collaboration with SRI will further improve our R&D abilities, drug manufacturing, and services delivery. I believe this collaboration will be highly successful," he continued.

The collaboration is part of SRI's long-term strategy to leverage global resources and meet evolving market needs. SRI has also formed a strategic partnership with WI Harper Group, a leading Pan-Pacific venture capital firm, which will collaborate with SRI on business development and partnering activities with its extensive network in the region.

"We are excited to build this 'Asia life sciences bridge' with SRI, and believe this will be a compelling new paradigm for drug development in the future," said Peter Liu, chairman of WI Harper Group.

As part of the agreement, NDSER will perform various preclinical development projects on behalf of SRI and its clients, including toxicology, pharmacology, formulation and analytic testing and research. SRI will manage the entire process and handle all technical diligence and regulatory oversight for preclinical drug development.

NDSER is a leading contract research organization in Shanghai's Zhangjiang Business Park in the Pudong business and financial district. The Park focuses primarily on information technology and biotechnology. It currently has 34 GMP facilities, 20 R&D units, and more than 90 start-up companies.

"Pudong is establishing a platform to support the development of a life sciences industry," said Shang Yu Ying, vice mayor of Pudong. "We are especially happy to have SRI as a prestigious partner in this strategic initiative."

About SRI International

Silicon Valley-based SRI International ( is one of the world's leading independent research and technology development organizations. Founded as Stanford Research Institute in 1946, SRI has been meeting the strategic needs of clients for 57 years. The nonprofit research institute performs contract research and development for government agencies, commercial businesses and nonprofit foundations. In addition to conducting contract R&D, SRI licenses its technologies, forms strategic partnerships and creates spin-off companies.

SRI's Biosciences Division works with government agencies and commercial pharmaceutical companies, large and small, to provide a broad range of preclinical discovery and development services in a GLP and cGMP environment. Last year, the division worked with more than 120 commercial clients, and during its 50-year history of preclinical development work, has performed FDA-compliant services on more than 30 marketed drugs and more than 100 drugs in clinical trials. Throughout its history, SRI also has an unprecedented 100 percent study acceptance rate with the FDA.
COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Aug 18, 2003
Previous Article:Borland Software Corporation and Spectrum Systems Collaborate to Enhance Software Capabilities of Federal Government Agencies.
Next Article:Hemispherx Biopharma Enters into Sales and Marketing Agreement with Engitech for Alferon N; Agreement Provides Nationwide Sales Team for Alferon N.

Related Articles
SRI International Announces New Vaccine Development Director, Rae Lyn Burke.
National Cancer Institute Selects SRI International Breast Cancer Therapeutic for Further Development.
National Science Foundation Selects SRI International to Evaluate Impact of Ubiquitous Computing in Classrooms.
National Cancer Institute Selects SRI International's Novel AKT Inhibitor Drug for Further Development as a Cancer Chemopreventative.
National Cancer Institute Awards SRI International an R33 'Fast-Track' Grant for Innovative Drug Toxicology Models.
Making sense of societal issues.
Industry datebook.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters